Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation presenting as pericardial effusion
In the evolving field of hematology and oncology, addressing acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is crucial. A recent study highlighting AML relapse as…
EHA China Spotlight | Professor Jing Pan: Previous-Transplant or New-Match Donor CD5 CAR-T Cells in Pediatric and Adult Relapsed/Refractory T-ALL: First-In-Human, Phase 1 Study
CAR-T cell therapy is rapidly advancing in the field of hematologic malignancies, including significant progress in the treatment of T-cell lymphomas. However, challenges such as relapse, off-target effects, and viral…
ASCO China Voice | Professor Jian Zhang: The First ADC Targeting Nectin-4, 9MW2821, Shows Promising Efficacy and Safety in Multiple Cancers
Editor's Note: Nectin-4 has emerged as a highly expressed adhesion molecule in various solid tumors, becoming a popular target in recent research. 9MW2821, developed using an internationally leading ADC development…
EHA Expert Interview | Professor Zhiming Li: Zanubrutinib Combined with CHOP Shows Superior Efficacy in Newly Diagnosed DLBCL Patients, Especially in the GCB Subtype
In the treatment of diffuse large B-cell lymphoma (DLBCL), the R-CHOP regimen has been a cornerstone, but enhancing its efficacy remains a significant challenge in the medical community. At the…
EASL Liver Cancer Summit | HNF1A Gene: Unlocking the “Key” to Hepatocellular Carcinoma Risk – Exclusive Interview with Professor Mohamed Abdel Samie
Hepatocellular carcinoma (HCC), one of the most lethal tumors globally, has long been a research hotspot due to its complex pathogenesis involving interactions between genetics, metabolism, and viral infections. Recently, at the 2025 EASL Liver Cancer Summit held in Paris, France, a study by Professor Mohamed Abdel Samie's team from the Department of Hepatology and Gastroenterology at the National Liver Institute, Menoufia University, Egypt, revealed the crucial role of the HNF1A genotype in HCC risk. Oncology Frontier invited Professor Mohamed Abdel Samie to discuss the potential value of this gene in HCC screening and the impact of metabolic factors. We look forward to future personalized treatment strategies targeting specific genotypes bringing new breakthroughs in the prevention and treatment of HCC.
Professor Xichun Hu’s Team: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer
Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…
ASCO GI 2025 | Dr. Zhi Peng: Five-Year Survival Benefits from CheckMate 649 Bring New Hope for a Cure in Gastric Cancer Patients
CheckMate 649 is the first global Phase III trial to successfully evaluate a first-line immunotherapy regimen (nivolumab + chemotherapy) for advanced gastric cancer. The study’s primary results were first unveiled at the 2020 European Society for Medical Oncology (ESMO) Congress, and the pre-specified China subgroup data were presented for the first time at the 2021 American Association for Cancer Research (AACR) meeting. The findings demonstrated even greater benefits in Chinese patients compared to the global population, generating significant academic interest and establishing first-line immunotherapy plus chemotherapy as the standard of care for advanced gastric cancer in China. Today, nivolumab in combination with chemotherapy has been approved as a first-line treatment for advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), and esophageal adenocarcinoma (EAC) in more than 50 countries, including the United States and China.
EHA Expert Interview | Professors Huilai Zhang and Shiyong Zhou’s Team: Major Advances in Lymphoma Research
The 29th European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain, from June 13-16, 2024. As the largest international conference in the field of hematology in Europe,…
ASCO China Voice | Prof. Xichun Hu’s Team: Phase II/III Trial of ARX788 vs. Lapatinib + Capecitabine for HER2+ ABC
Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…